Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Difluprednate

FDA-approved product (emulsion, ophthalmic), marketed as Difluprednate, Durezol.

Registered studies
25
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Difluprednate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anterior uveitis
  • Eye inflammation
  • Inflammation

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

25registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Difluprednate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Difluprednate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)

    NCT00616070 · start 2007-12

    Registered record
    Registry ID
    NCT00616070
    Conditions
    Inflammation
    Interventions
    Difluprednate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation
    InterventionDifluprednate; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation

    NCT00406341 · start 2004-04

    Registered record
    Registry ID
    NCT00406341
    Conditions
    Inflammation
    Interventions
    Difluprednate Ophthalmic Emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2005-03
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation
    InterventionDifluprednate Ophthalmic Emulsion
    PhasePhase 3
    Registry statusCompleted

  • Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation

    NCT00406497 · start 2003-04

    Registered record
    Registry ID
    NCT00406497
    Conditions
    Inflammation
    Interventions
    Difluprednate Ophthalmic Emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-04
    Completion
    2003-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation
    InterventionDifluprednate Ophthalmic Emulsion
    PhasePhase 2
    Registry statusCompleted

  • Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis

    NCT00406887 · start 2002-08

    Registered record
    Registry ID
    NCT00406887
    Conditions
    Anterior Uveitis; Panuveitis
    Interventions
    Difluprednate Ophthalmic Emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-08
    Completion
    2003-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnterior Uveitis; Panuveitis
    InterventionDifluprednate Ophthalmic Emulsion
    PhasePhase 3
    Registry statusCompleted

  • Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis

    NCT00407056 · start 2002-08

    Registered record
    Registry ID
    NCT00407056
    Conditions
    Uveitis; Panuveitis
    Interventions
    Difluprednate Ophthalmic Emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-08
    Completion
    2003-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis; Panuveitis
    InterventionDifluprednate Ophthalmic Emulsion
    PhasePhase 3
    Registry statusCompleted

  • Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis

    NCT00405496 · start 2000-03

    Registered record
    Registry ID
    NCT00405496
    Conditions
    Anterior Uveitis
    Interventions
    Difluprednate Ophthalmic Emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-03
    Completion
    2001-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnterior Uveitis
    InterventionDifluprednate Ophthalmic Emulsion
    PhasePhase 2
    Registry statusCompleted

  • Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation

    NCT00407225 · start 1999-12

    Registered record
    Registry ID
    NCT00407225
    Conditions
    Inflammation
    Interventions
    Difluprednate Ophthalmic Emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-12
    Completion
    2000-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation
    InterventionDifluprednate Ophthalmic Emulsion
    PhasePhase 2
    Registry statusCompleted

  • Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)

    NCT00429923

    Registered record
    Registry ID
    NCT00429923
    Conditions
    Inflammation
    Interventions
    Difluprednate; Difluprednate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation
    InterventionDifluprednate; Difluprednate; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)

    NCT00430092

    Registered record
    Registry ID
    NCT00430092
    Conditions
    Inflammation
    Interventions
    Difluprednate; Difluprednate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation
    InterventionDifluprednate; Difluprednate; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of Difluprednate in the Treatment of Uveitis

    NCT00501579

    Registered record
    Registry ID
    NCT00501579
    Conditions
    Uveitis
    Interventions
    Difluprednate; Prednisolone Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis
    InterventionDifluprednate; Prednisolone Acetate
    PhasePhase 3
    Registry statusCompleted